Fate therapeutics to host virtual event highlighting interim phase 1 clinical data from its off-the-shelf, ipsc-derived nk cell franchise for b-cell lymphoma

San diego, july 16, 2021 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim phase 1 clinical data from its ft596 and ft516 programs for the treatment of relapsed / refractory b-cell lymphomas on august 19, 2021 at 4:30 p.m. et.
FATE Ratings Summary
FATE Quant Ranking